SavedAdd your journal

Journals / Acta Medica / 2020 / Cilt: 51 - Sayı: 1

Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients

Seval Müzeyyen ERCİN
Nursel ÇALIK BAŞARAN
Murat ALADAĞ
Pages
9–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatit B virus DNA levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: HBV infection is a global public health problem.
📊
Key Findings & Data:Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection.
💡
Conclusion & Impact:Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatit B virus DNA levels.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: HBV infection is a global public health problem. Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection. The aim of this study was to evaluate treatment response and efficacy of Tenofovir disoproxil fumarate. Materials and Methods: The study included hepatitis B positive patients who started to use Tenofovir disoproxil fumarate. We retrospectively reviewed electronic medical files of Hepatitis B patients. Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B e antigens, Hepatitis B e antibody, Hepatitis B viral DNA, aspartate aminotransferase, alanine aminotransferase values were evaluated in the 1st, 3rd, 6th, 9th, and 12th months. Result: None of the patients under Tenofovir disoproxil fumarate treatment was “primary resistant”. Alanine aminotransferase normalization at 12th month was seen in 80.4% of study population. Hepatitis B surface antigen seroconversion was detected only in one patient (0.85%) at 9th months and Hepatitis B e antigen seroconversion was observed in 9 patients (8.3%) under Tenofovir disoproxil fumarate treatment. At the sixth month of Tenofovir disoproxil fumarate treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%). Among Hepatitis B e antigen positive patients, 44 (80 %) patients had undetectable Hepatitis B virus DNA levels at the end of 12th month and among Hepatitis B e antigens negative patients, 52 (91.2%) patients had undetectable Hepatitis B DNA levels at the end of 12th month (p<0.01). Conclusion: Among patients with chronic HBV infection, Tenofovir disoproxil fumarate had satisfying antiviral efficacy. There is no primary resistance in patients treated with Tenofovir disoproxil fumarate. Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatit B virus DNA levels.

🔖

Cite This Article

ERCİN, S. M., BAŞARAN, N. Ç., ALADAĞ, M. (2020). Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients. Acta Medica, Cilt: 51 - Sayı: 1, 9–14. https://ajindex.com/articles/141620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international 2016; 10(1): 1-98
  2. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43: S173-S81
  3. McMahon BJ. Epidemiology and natural history of hepatitis B. Seminars in liver disease 2005;25(1):3-8
  4. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007;45(1):97-01
  5. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560-99
  6. Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295(1):65-73
  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-39
  8. Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology 2016;1(3):185-95
  9. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clinical Gastroenterology and Hepatology 2007;5(8):890-7
  10. ABIM laboratory test reference ranges. https://www.abim. org/~/media/ABIM%20Public/Files/pdf/exam/laboratory-reference-ranges.pdf (Accessed January 2020
  11. Tang LS, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: A Review. Jama 2018;319(17):1802-13
  12. Güzelbulut F, Ovünç A, Oetinkaya Z, et al. Comparison of the efficacy of entecavir and tenofoviin chronic hepatitis B. Hepato-gastroenterology 2012;59(114):477-80
  13. Başarir İ, İlikhan S, Soyaltin UE. Kronik aktif hepatit B tanılı hastalarımızın tedavi yanıtlarının değerlendirilmesi. Akademik Gastroenteroloji Dergisi 2013; 12(2):58-65
  14. Demir NA, Kölgelier S, Demir LS. Naif Kronik Hepatit Bhastalarinin Bir Yillik 245 Mg/Gün Tenofovir Disoproksil Fumarate Tedavi Sonuçlarinin Değerlendirilmesi. Evaluation 2013; 21:25
  15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. The New England journal of medicine 2008;359(23):2442-55
  16. Woo G, To